O-GlcNAcase
From Proteopedia
(Difference between revisions)
| Line 39: | Line 39: | ||
**[[5m7t]] - hOGA + PUGNAc derivative<br /> | **[[5m7t]] - hOGA + PUGNAc derivative<br /> | ||
**[[5uho]] - hOGA TIM barrel and stalk domains + PUGNAc<br /> | **[[5uho]] - hOGA TIM barrel and stalk domains + PUGNAc<br /> | ||
| + | **[[5mi6]] - hOGA + transition state analog + inhibitor<br /> | ||
**[[2j62]] - CpOGA + GlcNAcstatin<br /> | **[[2j62]] - CpOGA + GlcNAcstatin<br /> | ||
**[[2wb5]], [[2x0y]], [[2xpk]], [[5oxd]] - CpOGA + inhibitor<br /> | **[[2wb5]], [[2x0y]], [[2xpk]], [[5oxd]] - CpOGA + inhibitor<br /> | ||
| + | **[[7khv]] - CpOGA (mutant) + pyrimidine derivative<br /> | ||
**[[2vvs]], [[2wca]] - BtOGA + PUGNAc<br /> | **[[2vvs]], [[2wca]] - BtOGA + PUGNAc<br /> | ||
**[[2j4g]], [[2w4x]], [[2vvn]], [[2w66]], [[2w67]], [[2xj7]], [[2xm1]], [[4aiu]], [[4ais]], [[2wzi]], [[2wzh]], [[4ur9]], [[5fky]], [[5fl0]], [[5fl1]] - BtOGA + inhibitor<br /> | **[[2j4g]], [[2w4x]], [[2vvn]], [[2w66]], [[2w67]], [[2xj7]], [[2xm1]], [[4aiu]], [[4ais]], [[2wzi]], [[2wzh]], [[4ur9]], [[5fky]], [[5fl0]], [[5fl1]] - BtOGA + inhibitor<br /> | ||
| Line 50: | Line 52: | ||
**[[5mi5]], [[5mi7]] - BtOGA + PUGNAc + inhibitor<br /> | **[[5mi5]], [[5mi7]] - BtOGA + PUGNAc + inhibitor<br /> | ||
**[[2x0h]] - BtOGA + michaelis complex<br /> | **[[2x0h]] - BtOGA + michaelis complex<br /> | ||
| - | **[[5mi6]] - hOGA + transition state analog + inhibitor<br /> | ||
**[[2xsb]] - OgOGA + PUGNAc<br /> | **[[2xsb]] - OgOGA + PUGNAc<br /> | ||
| + | **[[7khs]] - OgOGA catalytic domain 1-447 + pyrimidine derivative<br /> | ||
*O-GlcNAcase complex with polypeptide | *O-GlcNAcase complex with polypeptide | ||
Revision as of 09:25, 1 December 2021
| |||||||||||
3D structures of O-GlcNAcase
Updated on 01-December-2021
References
- ↑ Shen DL, Gloster TM, Yuzwa SA, Vocadlo DJ. Insights into O-linked N-acetylglucosamine ([0-9]O-GlcNAc) processing and dynamics through kinetic analysis of O-GlcNAc transferase and O-GlcNAcase activity on protein substrates. J Biol Chem. 2012 May 4;287(19):15395-408. doi: 10.1074/jbc.M111.310664. Epub, 2012 Feb 6. PMID:22311971 doi:http://dx.doi.org/10.1074/jbc.M111.310664
- ↑ Selnick HG, Hess JF, Tang C, Liu K, Schachter JB, Ballard JE, Marcus J, Klein DJ, Wang X, Pearson M, Savage MJ, Kaul R, Li TS, Vocadlo DJ, Zhou Y, Zhu Y, Mu C, Wang Y, Wei Z, Bai C, Duffy JL, McEachern EJ. Discovery of MK-8719, a Potent O-GlcNAcase Inhibitor as a Potential Treatment for Tauopathies. J Med Chem. 2019 Nov 27;62(22):10062-10097. doi: 10.1021/acs.jmedchem.9b01090., Epub 2019 Sep 29. PMID:31487175 doi:http://dx.doi.org/10.1021/acs.jmedchem.9b01090
- ↑ Yuzwa SA, Shan X, Macauley MS, Clark T, Skorobogatko Y, Vosseller K, Vocadlo DJ. Increasing O-GlcNAc slows neurodegeneration and stabilizes tau against aggregation. Nat Chem Biol. 2012 Feb 26;8(4):393-9. doi: 10.1038/nchembio.797. PMID:22366723 doi:http://dx.doi.org/10.1038/nchembio.797
- ↑ Roth C, Chan S, Offen WA, Hemsworth GR, Willems LI, King DT, Varghese V, Britton R, Vocadlo DJ, Davies GJ. Structural and functional insight into human O-GlcNAcase. Nat Chem Biol. 2017 Mar 27. doi: 10.1038/nchembio.2358. PMID:28346405 doi:http://dx.doi.org/10.1038/nchembio.2358
